News | January 06, 2026
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Subscribe To Our Newsletter & Stay Updated
